Edwards Lifesciences Corp
StreetZero Signal 56
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation is a public medical technology company headquartered in Irvine, California, specializing in tissue heart valves, transcatheter technologies, and surgical valve technologies for the treatment of advanced cardiovascular diseases. Founded in 1958, the company operates worldwide and reported revenue of US$6.07 billion in 2025. It is traded on the NYSE under ticker EW as an S&P 500 component.
LATEST FUNDINGRule 144
$194K
Announced 2026-11-10
IN THE NEWS
- 🔗 Edwards Lifesciences Corp
- 🔗 Edwards Lifesciences - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 Edwards Lifesciences - Wikipedia
- 🔗 Edwards Lifesciences initiates $100 million social impact investment fund to advance racial equity | Edwards Lifesciences
- 🔗 Edwards Lifesciences executive plans sale of 5,487 company shares | EW SEC Filing - Form 144
EMPLOYEES16000
FOUNDED1958
HQIrvine, CA, United States
Industry
Public Equity (NYSE)
Tags
Medical TechnologyPublic CompanyCardiovascular
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Public company on NYSE: EW with 2025 revenue of $6.07 billion.
- Specializes in heart valves and transcatheter technologies.
- Completed multiple acquisitions including Vectorious Medical Technologies for $497M in 2025.
- Established a $100 million Social Impact Investment Fund in 2021 focused on racial equity.
- Rule 144 filing covers small executive share sale of $193,592 with no disclosed backers.
Ask StreetZero about Edwards Lifesciences Corp
Put our AI to work on this deal.
Similar companies
Other Public Equity (NYSE) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account